logo-loader
Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals posts 3Q results, teases 2020 revenue boost from ophthalmology partnership

Under an exclusive distribution deal signed in July, Aequus will receive commercial rights to the Evolve line of preservative-free dry eye products

Eye close up
For the three months ended September 30, Aequus saw revenue of $370,799, a 12% dip year-over-year

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCMKTS:AQSZF) posted third-quarter results after the bell on Friday, which highlighted potential future revenue from a new ophthalmology partnership. 

“Aequus has continued to advance the business in Q3, signing a key collaboration with Medicom Healthcare [Ltd] which adds a collection of market-ready ophthalmology products along with late-stage development assets to our growing ophthalmology franchise in Canada,” CEO and Chairman Doug Janzen said in a statement. “This collaboration with Medicom fits perfectly into our goals and vision for the franchise. Aequus looks forward to continuing our business development efforts in the coming quarters and finishing the year strong with our current set of revenue-generating products.”

READ: Aequus Pharmaceuticals highlights new research showing Vistitan's effectiveness at treating glaucoma

Under an exclusive distribution agreement signed in July, Aequus will receive commercial rights to the Evolve line of preservative-free dry eye products. The products contain five commercial-stage products and two products in development, the company said.

Aequus has completed its regulatory work on the Health Canada applications and said it expects to file with the agency once it receives an audit report from Medicom. Looking ahead, the company expects to launch Evolve products in 2020.

For the three months ended September 30, Aequus saw revenue of $370,799, a 12% dip year-over-year. The reason for the decline, the company said, was a particularly strong quarter in 2018, coupled with a previously announced decrease in royalty share at the beginning of 2019.

“Despite the challenges of a decrease in the partner royalties, volume growth in ophthalmology grew by 81% Q3 2019 vs Q3 2018,” Chief Commercial Officer Ian Ball said in a statement. “Additionally, our year to date volume growth in 2019 vs 2018 grew by 60% which demonstrates the momentum that our commercial organization is generating.”

The company also said it has paused promotion of its Zepto Capsulotomy System, an eye surgery tool, while modifications are made by the manufacturer. The move is not expected to affect 2020 revenues.

Aequus added that it does expect to see product sales growth for its Tacrolimus and Vistitan ophthalmology offerings.

Aequus operates by taking medications that are already available in the US or elsewhere and licensing or acquiring the Canadian rights, then taking the clinical data that supported that approval and working with Health Canada, the country's national health system, to get them approved and commercialized.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.14 CAD

Market: TSX-V
Market Cap: $11.26 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Aequus Pharmaceuticals acquires Canadian rights to therapies for Dry Eye

Aequus Pharmaceuticals (CVE:AQS-OTCQB-) Chairman and CEO Doug Janzen sat down with Steve Darling from Proactive Investors Vancouver to discuss the company acquiring the Canadian rights to a line of products that help people deal with Dry Eye. 

on 13/3/19

2 min read